Neutralizing and Non-neutralizing Monoclonal Antibodies Against Dengue Virus E Protein Derived from a Naturally Infected Patient

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2010 Feb 6

PMID 20132551

Citations 48

Authors

John S Schieffelin

Joshua M Costin

Cindo O Nicholson

Nicole M Orgeron

Krystal A Fontaine

Sharon Isern

Scott F Michael

James E Robinson

Affiliations

Soon will be listed here.

Abstract

Background: Antibodies produced in response to infection with any of the four serotypes of dengue virus generally provide homotypic immunity. However, prior infection or circulating maternal antibodies can also mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic infection. Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic roles of the humoral immune system in dengue virus infection.

Results: Epstein-Barr Virus (EBV) transformation of B cells isolated from the peripheral blood of a human subject with previous dengue infection was performed. B cell cultures were screened by ELISA for antibodies to dengue (DENV) envelope (E) protein. ELISA positive cultures were cloned by limiting dilution. Three IgG1 human monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and biolayer interferometry. Neutralization and enhancement assays were conducted in epithelial and macrophage-like cell lines, respectively. All three HMAbs bound to E from at least two of the four DENV serotypes, one of the HMAbs was neutralizing, and all were able to enhance DENV infection.

Conclusions: HMAbs against DENV can be successfully generated by EBV transformation of B cells from patients at least two years after naturally acquired DENV infections. These antibodies show different patterns of cross-reactivity, neutralizing, and enhancement activity.

Citing Articles

The dengue-specific immune response and antibody identification with machine learning.

Natali E, Horst A, Meier P, Greiff V, Nuvolone M, Babrak L NPJ Vaccines. 2024; 9(1):16.

PMID: 38245547 PMC: 10799860. DOI: 10.1038/s41541-023-00788-7.

Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of .

Raeisi H, Azimirad M, Aghdaei H, Zarnani A, Abdolalizadeh J, Yadegar A Microbiol Spectr. 2023; :e0531022.

PMID: 37668373 PMC: 10580902. DOI: 10.1128/spectrum.05310-22.

When does humoral memory enhance infection?.

Nikas A, Ahmed H, Moore M, Zarnitsyna V, Antia R PLoS Comput Biol. 2023; 19(8):e1011377.

PMID: 37603552 PMC: 10470880. DOI: 10.1371/journal.pcbi.1011377.

Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19.

Boldova A, Korobkin J, Nechipurenko Y, Sveshnikova A Int J Mol Sci. 2022; 23(19).

PMID: 36232664 PMC: 9569501. DOI: 10.3390/ijms231911364.

Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification.

Ripoll D, Chaudhury S, Wallqvist A PLoS Comput Biol. 2021; 17(3):e1008864.

PMID: 33780441 PMC: 8032195. DOI: 10.1371/journal.pcbi.1008864.

References

Halstead S . Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970; 42(5):350-62. PMC: 2591710. View

Morita K, Tanaka M, Igarashi A . Rapid identification of dengue virus serotypes by using polymerase chain reaction. J Clin Microbiol. 1991; 29(10):2107-10. PMC: 270281. DOI: 10.1128/jcm.29.10.2107-2110.1991. View

Looney R, Ryan D, Takahashi K, Fleit H, Cohen H, Abraham G . Identification of a second class of IgG Fc receptors on human neutrophils. A 40 kilodalton molecule also found on eosinophils. J Exp Med. 1986; 163(4):826-36. PMC: 2188084. DOI: 10.1084/jem.163.4.826. View

Gromowski G, Barrett N, Barrett A . Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008; 82(17):8828-37. PMC: 2519678. DOI: 10.1128/JVI.00606-08. View

Cuzzubbo A, Endy T, Nisalak A, Kalayanarooj S, Vaughn D, Ogata S . Use of recombinant envelope proteins for serological diagnosis of Dengue virus infection in an immunochromatographic assay. Clin Diagn Lab Immunol. 2001; 8(6):1150-5. PMC: 96242. DOI: 10.1128/CDLI.8.6.1150-1155.2001. View

Roehrig J, Bolin R, Kelly R . Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998; 246(2):317-28. DOI: 10.1006/viro.1998.9200. View

Morens D, Venkateshan C, Halstead S . Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J Gen Virol. 1987; 68 ( Pt 1):91-8. DOI: 10.1099/0022-1317-68-1-91. View

Crill W, Roehrig J . Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001; 75(16):7769-73. PMC: 115016. DOI: 10.1128/JVI.75.16.7769-7773.2001. View

Modis Y, Ogata S, Clements D, Harrison S . A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003; 100(12):6986-91. PMC: 165817. DOI: 10.1073/pnas.0832193100. View

10.

Yeager M, Kumar S, Hughes A . Sequence convergence in the peptide-binding region of primate and rodent MHC class Ib molecules. Mol Biol Evol. 1997; 14(10):1035-41. DOI: 10.1093/oxfordjournals.molbev.a025709. View

11.

Halstead S . Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003; 60:421-67. DOI: 10.1016/s0065-3527(03)60011-4. View

12.

Sukupolvi-Petty S, Austin S, Purtha W, Oliphant T, Nybakken G, Schlesinger J . Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007; 81(23):12816-26. PMC: 2169112. DOI: 10.1128/JVI.00432-07. View

13.

Huang K, Yang Y, Lin Y, Huang J, Liu H, Yeh T . The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol. 2006; 176(5):2825-32. DOI: 10.4049/jimmunol.176.5.2825. View

14.

Johnson G, Wu T . Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunol. 1999; 10(12):1801-5. DOI: 10.1093/intimm/10.12.1801. View

15.

Schroeder Jr H . Similarity and divergence in the development and expression of the mouse and human antibody repertoires. Dev Comp Immunol. 2005; 30(1-2):119-35. DOI: 10.1016/j.dci.2005.06.006. View

16.

Collis A, Brouwer A, Martin A . Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol. 2002; 325(2):337-54. DOI: 10.1016/s0022-2836(02)01222-6. View

17.

Chaturvedi U, Shrivastava R, Nagar R . Dengue vaccines: problems and prospects. Indian J Med Res. 2005; 121(5):639-52. View

18.

Sabin A . Research on dengue during World War II. Am J Trop Med Hyg. 1952; 1(1):30-50. DOI: 10.4269/ajtmh.1952.1.30. View

19.

Hawkes R . ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS. Aust J Exp Biol Med Sci. 1964; 42:465-82. DOI: 10.1038/icb.1964.44. View

20.

Thu H, Lowry K, Myint T, Shwe T, Han A, Khin K . Myanmar dengue outbreak associated with displacement of serotypes 2, 3, and 4 by dengue 1. Emerg Infect Dis. 2004; 10(4):593-7. PMC: 3323074. DOI: 10.3201/eid1004.030216. View